Behind the headlines
Kayleigh Watts, from Addenbrooke’s Hospital in Cambridge has worked with people with frontotemporal dementia (FTD) and their loved ones during the Covid-19 pandemic. She reflects on the impact of COVID-19 on those with FTD, in a piece originally written for the Psychologist Magazine.
With your support, our scientists are looking closely at how DNA changes contribute to the diseases that cause dementia.
We know that if we can understand what increases the risk of developing dementia, governments and individuals can be better informed about how to reduce that risk.
The Pharmaceutical company Biogen plans to file for US marketing approval for aducanumab, an experimental treatment for early Alzheimer’s disease.
The results will naturally raise questions from anyone interested in the sport, so here’s everything you need to know about the findings.
We’re disappointed that Biogen AND Eisai have stopped two phase III trials of Alzheimer’s drug aducanumab. But we’re encouraged by the growing number of new avenues being explored by researchers across the world. Their work has never been more important.
Pfizer’s move in January was a shifting in research and development priorities to move away from neurodegeneration research carried out in-house in favour of other areas of research, while continuing to invest in other avenues to support neurodegeneration research – like their continued support of the Dementia Discovery Fund.
We know that there are many factors that contribute to dementia risk. There is no surefire way to prevent dementia. Limiting alcohol consumption may be one way to reduce risk but people can develop the condition regardless of alcohol use.
Recent news from the pharmaceutical industry that Pfizer is reducing its investment in dementia research has highlighted some of the barriers to research, and the increased need for shared responsibility in bringing treatments to people in need.